CompletedPhase 2NCT00077922

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

Studying Bronchiolitis obliterans

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Robert J Kreitman, M.D., MFT
National Cancer Institute, National Institutes of Health
Intervention
LMB-2(drug)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
20042011

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00077922 on ClinicalTrials.gov

Other trials for Bronchiolitis obliterans

Additional recruiting or active studies for the same condition.

See all trials for Bronchiolitis obliterans

← Back to all trials